Pulmonology · Idiopathic Pulmonary FibrosisTrial Updatecompetitivemid-term

Phase 2 Study of PIPE-791 in Idiopathic Pulmonary Fibrosis Initiated by Contineum Therapeutics

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/2/2026, 12:30:38 PM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 2 trial for PIPE-791 by Contineum Therapeutics is significant as it introduces a potential competitor in the Idiopathic Pulmonary Fibrosis (IPF) treatment landscape. Positive trial outcomes could shift market dynamics and influence competitive positioning for existing therapies. Regulatory context from MHRA (Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis) supports the near-term read. Assessment grounded in 10 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial outcomes closely, as positive results could enhance Contineum's standing in the IPF market. The strongest clinical anchor is A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No (ClinicalTrials.gov), sub-indication match (ild). In ild, 1 regulatory and 3 competitive items passed relevance filtering for Contineum Therapeutics.

Competitive Pressure

The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from [Ad hoc announcement pursuant to Art.. This trial adds to the competitive landscape for IPF treatments, where efficacy and safety data will be critical for market positioning.

Regulatory Outlook

Regulatory risk is concentrated around Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis (MHRA). Sub-indication match (ild). The trial's outcomes will be crucial for regulatory submissions and could affect the approval timeline for PIPE-791, influencing market entry strategies.

Key Risks

Elevated medium regulatory exposure for Contineum Therapeutics could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If PIPE-791 demonstrates favorable efficacy and safety, it could capture market share from established IPF treatments, impacting revenue projections for competitors.
Portfolio teams should monitor the trial outcomes closely, as positive results could enhance Contineum's standing in the IPF market.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final efficacy data from the Phase 2 trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
MHRAhigh relevance
Sub-indication match (ild)
FDA document
View source
Clinical trials for medicines: MHRA phase I accreditation scheme
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Sub-indication match (ild)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Salvia miltiorrhiza Bunge alleviates pulmonary fibrosis by promoting fibroblast mitophagy.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Sub-indication match (ild)
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Contineum Therapeutics
PIPE-791

Commercial impact

medium

If PIPE-791 demonstrates favorable efficacy and safety, it could capture market share from established IPF treatments, impacting revenue projections for competitors.

Regulatory impact

medium

The trial's outcomes will be crucial for regulatory submissions and could affect the approval timeline for PIPE-791, influencing market entry strategies.

What to watch

Key milestones include interim results and final efficacy data from the Phase 2 trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.